1. Pink Sheet
  2. >>Agency Leadership
  3. >>US FDA

Partisan Politics Returns To US FDA Congressional Oversight

 
• By Michael McCaughan

The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.

Food and Drug Administration (FDA) Commissioner Robert Califf speaking at a hearing of the House Committee on Oversight and Accountability at the U.S. Capitol on April 4, 2024
FDA Commissioner Robert Califf had a tough outing on Capitol Hill. • Source: Michael Brochstein/SOPA Images/Shutterstock

An 11 April House Oversight Committee hearing with US Food and Drug Commissioner Robert Califf may be a sign that an era of relatively calm, bipartisan support for the agency on Capitol Hill is ending.

At a time when congressional Republicans and Democrats are at odds on so many aspects of government policy and public health, the FDA has generally remained above the fray. Even at the peak of the political battles over the COVID-19 response, members of Congress have been far more likely to attack the National Institutes of Health (“Prosecute Fauci!”) or the US Centers for Disease Control and Prevention (Mask or no mask?) than they have been to challenge the FDA

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from US FDA

Mayne’s Nextstellis Promo Wrong To Suggest Better Safety Than Other Contraceptives, FDA Says

 
• By Sue Sutter

A professional slide deck for the drospirenone/estetrol oral contraceptive inappropriately suggests it is safer than other estrogen-containing products and understates risks, Office of Prescription Drug Promotion said in the first “untitled” letter issued since reductions-in-force.

US FDA Waiting On Guidance Agenda Future As HHS Seeks Regulation Cuts

 
• By Derrick Gingery

The FDA continues to wait for a decision on whether its priority guidances will be published as HHS asks the public for potential regulation cuts to fulfill President Trump’s executive order.

Pink Sheet Podcast: A New Director For US FDA’s Biologics Center, Guidance Production Slowdowns

 
• By Derrick Gingery, Sue Sutter, and Nielsen Hobbs

Pink Sheet editors discuss the appointment of Vinay Prasad as the new director of the Center for Biologics Evaluation and Research and revelations that FDA layoffs now are hindering development of guidance documents.

US FDA Restoring Some Library Resources

 
• By Sue Sutter and Derrick Gingery

Agency staff once again have access to the Lexis-Nexis legal and news database, but are still waiting for access to journals, and laid off librarians have not been reinstated.

More from Agency Leadership